At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany, explains that the treatment of metastatic melanoma has been revolutionised by recent developments in immunotherapeutic agents, ipilimumab, an anti-CTLA-4 antibody, pembrolizumab, an anti-PD-1 antibody, and nivolumab, an anti-PD-1 antibody; targeted agents, the BRAF inhibitors, vemurafenib and dabrafenib; and the vaccine therapy, talimogene laherparepvec (T-VEC).
Changing the treatment landscape of metastatic melanoma
14th June 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?